Skip to main content

Featured Article : Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer

New Content ItemThe cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4)/B7 and programmed death 1 (PD-1)/ programmed cell death-ligand 1 (PD-L1) are two most representative immune checkpoint pathways, which negatively regulate T cell immune function during different phases of T-cell activation. Inhibitors targeting CTLA-4/B7 and PD1/PD-L1 pathways have revolutionized immunotherapies for numerous cancer types. Although the combined anti-CTLA-4/B7 and anti-PD1/PD-L1 therapy has demonstrated promising clinical efficacy, only a small percentage of patients receiving anti-CTLA-4/B7 or anti-PD1/PD-L1 therapy experienced prolonged survival. Regulation of the expression of PD-L1 and CTLA-4 significantly impacts the treatment effect. Understanding the in-depth mechanisms and interplays of PD-L1 and CTLA-4 could help identify patients with better immunotherapy responses and promote their clinical care. 

In this review, regulation of PD-L1 and CTLA-4 is discussed at the levels of DNA, RNA, and proteins, as well as indirect regulation of biomarkers, localization within the cell, and drugs. Specifically, some potential drugs have been developed to regulate PD-L1 and CTLA-4 expressions with high efficiency.

Aims and scope

Journal of Experimental & Clinical Cancer Research is an online peer-reviewed journal that provides a high-quality forum for all aspects of basic, clinical and translational work in oncology.

Please click here to read more.

Editor-in-Chief

Mauro Castelli, Regina Elena National Cancer Institute, Italy

If you would like to contact Journal of Experimental & Clinical Cancer Research, please send an email to: 

editorialjeccr@gmail.com

Articles

  1. Authors: Christopher Montemagno, Arnaud Jacquel, Charlotte Pandiani, Olivia Rastoin, Rosie Dawaliby, Thomas Schmitt, Maxence Bourgoin, Héliciane Palenzuela, Anne-Laure Rossi, Damien Ambrosetti, Jerome Durivault, Frederic Luciano, Delphine Borchiellini, Julie Le Du, Leticia Christina Pires Gonçalves, Patrick Auberger…

Springer Nature Oncology Portfolio

Discover the range of academic oncology titles at Springer Nature here.

Colorectal Cancer Awareness Month

In recognition of Colorectal Cancer Awareness Month this March, we have selected a collection of articles on colorectal cancer from across our open access portfolio. Together, these articles contribute to the evolving landscape of colorectal cancer research and the fight against this prevalent and impactful disease.
© Mopic / stock.adobe.com

Call for papers: Liquid Biopsy in Precision Oncology

New Content Item

Journal of Experimental & Clinical Cancer Research is delighted to announce a new thematic series focused on:

Liquid Biopsy in Precision Oncology

The Special Issue will accept Research Articles and Reviews in this topic. Submit here.

  • Submission opens: 1st February 2024
  • Submission deadline: 31st January 2025

Click here to view this collection. Click here to access all thematic series published to date in Journal of Experimental & Clinical Cancer Research.

Call for papers: CRISPR-Cas9 system, the next generation in cancer therapy and target discovery

New Content Item

Journal of Experimental & Clinical Cancer Research is delighted to announce a new thematic series focused on:

CRISPR-Cas9 system, the next generation in cancer therapy and target discovery

The Special Issue will accept Research Articles and Review in this topic. Submit here.

  • Submission opens: 1st April 2023
  • Submission deadline: 30th June 2024

Click here to view this collection. Click here to access all thematic series published to date in Journal of Experimental & Clinical Cancer Research.

Follow JECCR on Social Media

Social Media IconsTwitter

Facebook

LinkedIn

Follow JECCR's social media accounts to be kept up-to-date with the latest articles, collections and journal news!

Recognising Editorial Excellence

SN Editorial Excellence badgeJournal of Experimental & Clinical Cancer Research is a top rated Springer Nature journal. Prof. Mauro Castelli and the editorial team performed in the top percentile of journals based on data collected from the Journal Author Satisfaction Survey. We are recognising extraordinary editors for their commitment and passion to their journals. Read more about editorial excellence here.

Reviewer Acknowledgement and New Recruitment

The Editor-in-Chief of Journal of Experimental & Clinical Cancer Research would like to thank all of our reviewers who have contributed to the journal and is looking for new reviewers to assess manuscripts. For consideration, please send your CV with keywords and expertise to editorialjeccr@gmail.com

Archival content

Journal of Experimental & Clinical Cancer Research has been publishing since 1982.  Prior to publishing with BioMed Central from 2008, Journal of Experimental & Clinical Cancer Research was published in print.  For enquiries about previous content, please contact us on: 

editorialjeccr@gmail.com


Annual Journal Metrics

  • 2022 Citation Impact
    11.3 - 2-year Impact Factor
    11.5 - 5-year Impact Factor
    1.870 - SNIP (Source Normalized Impact per Paper)
    2.413 - SJR (SCImago Journal Rank)

    2023 Speed
    4 days submission to first editorial decision for all manuscripts (Median)
    100 days submission to accept (Median)

    2023 Usage 
    3,003,080 downloads
    3,022 Altmetric mentions